We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Intuit
INTU
$83.1B
| $15.1M | 0.1% |
30,881
-47,597
| -61% | -$20.6M |
|
|
227
Union Pacific
UNP
$178B
| $15.1M | 0.1% |
68,730
-211,381
| -75% | -$47.1M |
|
228
Bloom Energy
BE
$53.5B
| $15.1M | 0.1% |
562,311
+129,252
| +30% | +$3.13M |
|
229
argenx
ARGX
$55.6B
| $14.9M | 0.1% |
49,526
+10,753
| +28% | +$3.06M |
|
|
ATH
230
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $14.8M | 0.1% |
+219,060
| New | +$13.2M |
|
231
CytomX Therapeutics
CTMX
$708M
| $14.7M | 0.1% |
2,328,353
+2,328,207
| +1,594,662% | +$18.1M |
|
|
PRAH
232
DELISTED
PRA Health Sciences, Inc.
PRAH
| $14.5M | 0.1% |
+87,515
| New | +$14.6M |
|
233
Insmed
INSM
$22.7B
| $14.4M | 0.1% |
505,241
+222,340
| +79% | +$6.6M |
|
234
KLA
KLAC
$266B
| $14.2M | 0.1% |
436,740
-24,950
| -5% | -$799K |
|
235
KeyCorp
KEY
$24.1B
| $14M | 0.1% |
680,162
+245,884
| +57% | +$5.34M |
|
236
AT&T
T
$167B
| $13.9M | 0.1% |
640,780
-841,651
| -57% | -$19.1M |
|
237
TG Therapeutics
TGTX
$8.53B
| $13.7M | 0.09% |
353,983
-656,244
| -65% | -$25.8M |
|
238
Ecolab
ECL
$76.4B
| $13.7M | 0.09% |
66,509
-77,360
| -54% | -$16.8M |
|
239
Zscaler
ZS
$23.8B
| $13.6M | 0.09% |
62,914
+56,445
| +873% | +$10.7M |
|
240
Oracle
ORCL
$345B
| $13.5M | 0.09% |
173,069
-115,108
| -40% | -$9.01M |
|
241
Nurix Therapeutics
NRIX
$2.43B
| $13.5M | 0.09% |
507,303
+507,290
| +3,902,231% | +$14.9M |
|
242
Celldex Therapeutics
CLDX
$2.8B
| $13.4M | 0.09% |
399,685
+55,546
| +16% | +$1.52M |
|
243
Xenon Pharmaceuticals
XENE
$6.36B
| $13.3M | 0.09% |
+715,722
| New | +$13.2M |
|
244
Zai Lab
ZLAB
$2.1B
| $13.2M | 0.09% |
65,648
+65,643
| +1,312,860% | +$10.6M |
|
|
ITCI
245
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $13M | 0.09% |
319,487
-136,535
| -30% | -$5.05M |
|
246
General Mills
GIS
$19.5B
| $13M | 0.09% |
213,039
-71,394
| -25% | -$4.42M |
|
|
ITOS
247
DELISTED
iTeos Therapeutics
ITOS
| $13M | 0.09% |
504,890
+504,872
| +2,804,844% | +$12M |
|
248
Caterpillar
CAT
$402B
| $12.9M | 0.09% |
59,327
-142
| -0.2% | -$32.8K |
|
|
CHNG
249
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $12.8M | 0.09% |
+553,958
| New | +$12.7M |
|
|
KSU
250
DELISTED
Kansas City Southern
KSU
| $12.7M | 0.09% |
44,985
+535
| +1% | +$154K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.